Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Plus Therapeutics (PSTV) Return on Capital Employed (2016 - 2025)

Plus Therapeutics has reported Return on Capital Employed over the past 15 years, most recently at 295.13% for Q4 2025.

  • Quarterly Return on Capital Employed fell 46316.0% to 295.13% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 295.13% through Dec 2025, down 46316.0% year-over-year, with the annual reading at 1832.1% for FY2025, 160742.0% up from the prior year.
  • Return on Capital Employed was 295.13% for Q4 2025 at Plus Therapeutics, up from 1505.15% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 1229.48% in Q1 2025 and troughed at 1505.15% in Q3 2025.
  • The 5-year median for Return on Capital Employed is 119.44% (2022), against an average of 122.33%.
  • Year-over-year, Return on Capital Employed soared 99748bps in 2024 and then crashed -199083bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 89.81% in 2021, then plummeted by -89bps to 169.44% in 2022, then tumbled by -390bps to 829.45% in 2023, then soared by 120bps to 168.03% in 2024, then plummeted by -276bps to 295.13% in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Return on Capital Employed are 295.13% (Q4 2025), 1505.15% (Q3 2025), and 328.61% (Q2 2025).